MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance-Reference-Cited by-同舟云学术

MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance

Published:2021-09-23 Issue:11 Volume:112 Page:4478-4489
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Kobayashi Maki¹²³⁴,Kojima Katsuhiko⁵,Murayama Kazutaka⁶,Amano Yuji⁵^ORCID,Koyama Takashi¹²,Ogama Naoko¹,Takeshita Toshikazu⁵,Fukuhara Tatsuro³⁴^ORCID,Tanaka Nobuyuki¹²^ORCID

Affiliation:

1. Division of Tumor Immunobiology Miyagi Cancer Center Research Institute Natori Japan

2. Division of Tumor Immunobiology Tohoku University Graduate School of Medicine Sendai Japan

3. Division of Respiratory Oncology Tohoku University Graduate School of Medicine Sendai Japan

4. Department of Respiratory Medicine Miyagi Cancer Center Hospital Natori Japan

5. Department of Microbiology and Immunology Shinshu University School of Medicine Matsumoto Japan

6. Division of Biomedical Measurements and Diagnostics Tohoku University Graduate School of Biomedical Engineering Sendai Japan

Funder

Japan Agency for Medical Research and Development

Core Research for Evolutional Science and Technology

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15127

Reference51 articles.

1. Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity

2. The role of interleukin-2 during homeostasis and activation of the immune system

3. Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

4. Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γ c Receptors

5. The Interleukin-2 Receptor γ Chain: Its Role in the Multiple Cytokine Receptor Complexes and T Cell Development in XSCID

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy;International Immunopharmacology;2024-07

2. An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2;Cell Reports Medicine;2023-11

3. Essential role of an acidic endosomal environment in JAK3-mediated signal transduction;2023-09-12

4. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity;2023-05-04

5. Therapeutic potential of interleukin-2 in autoimmune diseases;Trends in Molecular Medicine;2022-07